Bonjela

Quick links to important sections

Bonjela

Treatment option: Canker Sore, Pain, Cold Sore, Infection, Cold

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bonjela

Quick Facts

Property Description
Active Ingredients Lidocaine Hydrochloride and Cetalkonium Chloride
Form Oral Gel (Topical Preparation)
Pharmacological Class Local Anesthetic and Antiseptic Combination
Common Use Symptomatic relief of localized oral soreness and discomfort
Origin Synthetic

Bonjela: Classification and Pharmaceutical Form

Bonjela is fundamentally defined as a synthetic combination product presented as an Oral Gel, intended solely for topical application to the oral mucosa. This product is generally available as an Over-The-Counter (OTC) medicine. Its identity is rooted in the synergistic blend of two distinct active agents. The primary anesthetic component, Lidocaine Hydrochloride, is a prototypical member of the amide class of local anesthetics. The dosage form, a pharmaceutical gel, is a mucoadhesive vehicle designed to ensure the active ingredients remain in prolonged contact with the mouth's lining, optimizing their localized effect.

Active Ingredients and Compositional Roles

The dual-action nature of this preparation is based on its two core active ingredients: Lidocaine Hydrochloride and Cetalkonium Chloride. Lidocaine Hydrochloride provides the essential Local Anesthetic function, resulting in the rapid reduction of discomfort. The second ingredient, Cetalkonium Chloride, belongs to the class of quaternary ammonium compounds, which function as surface-active Antiseptics. This combination is differentiated by its integrated approach, offering both powerful pain relief and hygiene support in a single application. The active compounds are suspended within a pharmaceutical gel base.

General Purpose of the Anesthetic-Antiseptic Combination

The general purpose of the anesthetic and antiseptic composition is to offer effective symptomatic relief for localized discomfort and soreness in the mouth. By combining the fast-acting numbing from the Local Anesthetic with the cleansing action of the Antiseptic, the preparation provides a targeted countermeasure to irritation. The fundamental utility of this product lies in its ability to immediately mitigate sensory discomfort while simultaneously aiding in the maintenance of cleanliness of the affected oral mucosa.

What side effects are possible with Bonjela?

Official Adverse Reactions and Safety Profile

The official safety documentation for the oral gel containing Lidocaine Hydrochloride and Cetalkonium Chloride describes possible adverse reactions based on regulatory classification systems. For this topical formulation, the frequency of many reported effects is often classified as Not Known, meaning it cannot be reliably estimated from available data.

Adverse reactions documented in official sources primarily involve Immune System Disorders and General Disorders and Administration Site Conditions.

Category Documented Adverse Reactions (Non-Systemic)
Local Reactions Transient burning sensation, stinging, or local irritation at the site of application.
Hypersensitivity Allergic reactions, including rare but serious events such as angioedema (swelling beneath the skin) and anaphylaxis.

The regulatory profile highlights specific constraints and risks related to the active anesthetic component, lidocaine. Use is strictly contraindicated in individuals with a known hypersensitivity to the active ingredients or to other amide-type local anesthetics.

Population-Specific Safety Considerations: Official government guidance has implemented specific restrictions for the use of lidocaine-containing products in infants and very young children due to the potential risk of serious adverse effects from systemic absorption, such as methaemoglobinaemia. The official profile warns that excessive dosage, short dosing intervals, or application to compromised oral mucosa increases the risk of high plasma levels and subsequent systemic toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the active ingredient Lidocaine Hydrochloride is characterized by systemic toxicity affecting the central nervous system (CNS) and the cardiovascular system. Documented presentations may initially include early CNS signs such as drowsiness, lightheadedness, confusion, dizziness, tinnitus, and tremors. Severe neurological manifestations can follow, including convulsions (seizures), unconsciousness, and respiratory arrest. Life-threatening cardiovascular effects described in regulatory labeling include bradycardia, hypotension, and cardiovascular collapse, which may progress to cardiac arrest.

A severe outcome explicitly documented in the overdose profile is the blood disorder methemoglobinemia, which is indicated by cyanotic skin discoloration (pale, gray, or blue skin). Infants and young children are identified in official labeling as a population at significantly increased risk of severe adverse events, including death, from overdose or accidental ingestion.

Immediate Action Required: Regulator-mandated instructions require that you seek immediate medical attention upon noting any signs of systemic toxicity (such as lethargy, shallow breathing, or seizure activity) or symptoms of methemoglobinemia. Treatment is primarily symptomatic and supportive, as defined in regulatory documents. This may include the use of oxygen therapy or resuscitative measures, with specific interventions like methylene blue required for certain severe outcomes. Discontinuation of the product is also mandated immediately upon suspicion of overdose.

Therapeutic Uses of Bonjela

What Bonjela Treats: Main Uses and Benefits

The preparation is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to physical discomfort within the mouth. Formulations containing lidocaine serve as part of symptomatic management for pain in settings involving acute or unstable symptom patterns affecting the oral mucosa.

It is generally used for managing symptom clusters that may become intense or disruptive, such as the localized soreness from common mouth ulcers, minor oral lesions, sore spots from dentures or orthodontic appliances, and discomfort during infant teething episodes. This use may assist with maintaining functional stability, and the product is considered relevant for easing symptoms that interfere with daily functioning.

“This symptomatic support is often used when discomfort arises from localized irritation, contributing to easing the overall symptom load during periods of heightened symptoms.”


Quick Fact Block

Property Description
Quick Fact: Relief for Localized Oral Pain
Typical Contexts Teething, Denture sores, Mouth ulcers
Core Benefit Provides support that helps ease the overall symptom burden

Regulatory References

  1. UK Government guidance on lidocaine teething products

Eligibility and Restrictions for Use

The official eligibility profile for Bonjela (Lidocaine/Cetalkonium Chloride formulation) is defined by specific regulatory exclusions and conditional use guidelines. The medicine is contraindicated in infants under 5 months of age. Use is also strictly prohibited for individuals with known hypersensitivity to the active ingredients, Lidocaine Hydrochloride or Cetalkonium Chloride, or to the chemical class of amide-type local anaesthetics. A further absolute prohibition applies to patients with a history of or suspected Methaemoglobinaemia.


Eligibility Category Status as per Regulatory Labeling
Minimum Age Contraindicated under 5 months; Permitted from 5 months and over.
Organ Function Use with caution is required for patients with hepatic dysfunction or cardiac dysfunction.
Pregnancy Status Not recommended (safety not established for human pregnancy).
Lactation Status Generally compatible with breast feeding.

The eligibility structure establishes absolute prohibitions based on minimum age, known ingredient hypersensitivity, and specific high-risk metabolic conditions, while imposing conditional restrictions related to pre-existing organ function. These guidelines determine who can and cannot use the medicine according to regulatory standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for the formulation containing Lidocaine Hydrochloride, strictly based on governmental regulatory sources. The interaction profile is classified by the type of effect observed when the product is co-administered with certain other medicines.

Documented Interaction Patterns

Type of Interaction Interacting Substance/Class Official Outcome Description
Increased Exposure/Toxicity Risk Cimetidine, Propranolol, Erythromycin, Itraconazole Concurrent use is documented to increase the risk of lidocaine toxicity, implying reduced clearance.
Additive Toxic Effects Other Local Anesthetics (Amide-type), Antiarrhythmic Drugs (e.g., Mexiletine) Toxic effects are officially noted as additive when co-administered.
Antagonism of Effect Diuretics causing Hypokalaemia The regulatory label documents that lidocaine is antagonised by these diuretics.
Specific Restriction Drugs Associated with Methemoglobinemia Co-administration may result in an increased risk of developing methemoglobinemia.

Summary of Regulatory Constraints

Use is contraindicated in patients with known hypersensitivity to local anesthetics of the amide type. Caution is also specified for patients with hepatic or cardiac dysfunction, as the risk associated with potential interactions and high plasma levels is heightened in these populations. The regulatory documentation does not explicitly state mandatory timing separation rules for co-administered medicines, nor are specific interactions with food, alcohol, or herbal products formally documented.

Mechanism of Action

How Bonjela Works: Mechanism of Action

The localized effect of this preparation arises from the coordinated action of two distinct mechanistic domains: Sensory Nerve Impulse Blockade and Microbial Cell Membrane Disruption.


Sensory Nerve Impulse Blockade

This domain covers the action of Lidocaine, which directly targets voltage-gated sodium channels ( Na v) embedded in peripheral sensory neurons. By acting as a use-dependent blocker, the drug stabilizes the channel in its inactive state, thereby physically preventing the influx of sodium ions required to propagate an electrical signal. This mechanism fundamentally interrupts the nociceptive signal transduction pathway, resulting in a localized cessation of nerve conduction.


Microbial Cell Membrane Disruption

This domain focuses on the mechanism of Cetalkonium Chloride, which operates as a cationic surfactant. Its positive charge allows it to bind electrostatically to the negatively charged bacterial cell membrane, acting as a membrane disruptor. This physical interaction compromises the membrane's integrity, leading to the leakage of essential cellular contents and subsequent microbial death. This mechanistic sequence results in a localized reduction in the microbial population on the oral mucosa.

Dosage and Administration Information

The official use of this oral preparation involves topical application directly to the oral mucosa using a clean finger or swab. This oromucosal administration is subject to strict frequency and volume constraints outlined in product labeling. The dose for adults typically involves massaging approximately one centimeter of the gel onto the area of discomfort. Application is limited to a minimum interval of three hours and must not exceed a maximum of six doses within any 24-hour period.

Dosing instructions and patient suitability are determined by the specific product formulation. While certain salicylate-containing products are restricted to use in individuals 16 years of age and over in some territories, alternative, non-salicylate gels containing lidocaine are specifically labeled for use in infants from 5 months of age, following their respective pediatric dose guidelines.

Contextual instructions govern proper administration in specific situations. Before treating mouth ulcers, the affected surface should be wiped clean of mucus to facilitate application. When used for discomfort related to dental appliances, the gel is applied to the mucosal tissue, and the appliance should remain removed for at least 30 minutes following application. The duration of self-managed use is time-bound; if the need for application persists beyond seven days, label instructions indicate that professional advice must be sought.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Bonjela (Lidocaine/Cetalkonium Chloride)


Evidence for Symptomatic Relief in Minor Oral Pain (Mouth Ulcers)

Research exploring the use of topical gels for oral lesions includes Randomized Controlled Trials (RCTs) focused on the local anesthetic component alone or against inactive controls. These studies examine outcomes related to change in pain intensity and localized soreness levels in adults and adolescents. The overall classification of this use as "well-established" is based on the known pharmacological profile of the anesthetic drug class. However, robust data providing clear insight into the specific contribution of the antiseptic component within this combination gel is often not clearly defined in published efficacy studies.

Research Landscape for Localized Discomfort from Dental Devices

Studies for localized discomfort from appliances like dentures or orthodontic braces rely largely on clinical experience summaries and regulatory reviews. The studies explored patient-reported outcomes related to soreness relief in adults and adolescents using these devices. Regulatory acceptance is based on the general understanding of the rapid, topical numbing property that the anesthetic ingredient may provide to mucosal tissues. Formal, blinded RCTs specifically assessing the combination gel for device-related mucosal trauma are scarce in the publicly available literature.


Evidence Structure Regarding Teething Discomfort in Infants

The research base for lidocaine-containing products used for teething discomfort includes trials with limited sample sizes and retrospective analyses. Official reviews conducted by major regulatory bodies, such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA), have noted that there is a lack of convincing evidence clearly characterizing the effect for oral lidocaine products in treating teething specifically, especially when compared to non-medicinal approaches. Research has emphasized that existing studies frequently have limitations, including difficulties in reliably measuring pain in infants.

Long-Term Research and Follow-up Durations

The available research for this topical gel primarily focuses on acute and short-term symptom relief. Follow-up durations were limited across all indications, ranging from a few minutes post-application to a maximum of one to two weeks. There is limited information for long-term outcomes, as research exploring the durability of response or the effects on recurring conditions are not well characterized in the public research record for this specific product.

Key Studies & References

  1. Oral lidocaine-containing products for infant teething: only to be available under the supervision of a pharmacist - GOV.UK
  2. Oral lidocaine products: risk minimisation measures for use in teething - GOV.UK (Public Assessment Report)
  3. Efficacy of Topical 1% Lidocaine in the Symptomatic Treatment of Pain Associated With Oral Mucosal Trauma or Minor Oral Aphthous Ulcer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose Study

Frequently Asked Questions (FAQ)

Common questions about Bonjela (FAQ)


Q: Why is the Bonjela Adult formula not recommended for use in children under 16 years old?

Regulatory documents state that use of the salicylate-containing product in children and adolescents under the age of 16 is restricted. This is due to a possible association between salicylates, when given to children, and Reye's syndrome. This is a precautionary measure aligned with the official guidelines for other products containing salicylates.


Q: What is the main difference in active ingredients between Bonjela Adult and Bonjela Teething Gel?

The official compositions of these products differ significantly based on regulatory jurisdiction and intended use. Adult formulas typically contain Choline Salicylate, which is an anti-inflammatory pain reliever, and Cetalkonium Chloride. Teething or Junior gels for younger children generally contain Lidocaine Hydrochloride, a local anesthetic, and Cetylpyridinium Chloride.


Q: What is the risk of Reye's syndrome and how does it relate to the use of Bonjela?

Reye's syndrome is officially noted as a very rare disease affecting the brain and liver that can be fatal. This is the basis for the precautionary restriction of salicylate-containing products in children and adolescents under 16 years of age. Regulatory agencies have aligned the safety advice for topical salicylates with that for oral aspirin.


Q: Does Bonjela help with pain relief from cold sores, and can it be used on a sore outside the mouth?

Official product indications for the salicylate-containing gel include the relief of pain, discomfort, and inflammation caused by common mouth ulcers and cold sores. However, regulatory labels generally specify the product is for topical application to the oral mucosa, which is the lining inside the mouth.


Q: What should I do if a child accidentally swallows a small amount of Bonjela gel?

Symptoms of systemic toxicity (salicylate poisoning) can include effects such as ringing in the ears, dizziness, nausea, and rapid breathing. The official guidance for over-exposure advises that medical advice or attention should be sought.


Q: How quickly should I expect Bonjela to start relieving the pain?

The anesthetic ingredient is designed to block sensory nerve signals, and the local numbing property is generally understood to occur quickly after application. The product's mechanism of action is based on the rapid, topical effect of the anesthetic component.


Q: How long does the numbing effect of Bonjela typically last on a mouth ulcer?

Regulatory instructions for both the salicylate and lidocaine gels generally recommend a minimum interval of three hours between doses. The minimum interval between applications is a regulatory safety constraint of three hours, and this period should be respected before any reapplication.


Q: Does Bonjela have known interactions with common pain relievers like paracetamol or ibuprofen?

The official product information for the salicylate-containing gel advises caution or advises against co-use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, or aspirin. This is due to a potential risk of additive side effects or toxicity.


Q: Can the salicylate ingredient in Bonjela cause problems for people with aspirin sensitivity?

Official documents advise that the salicylate-containing gel is contraindicated, meaning it should not be used, in patients who have a known hypersensitivity to salicylates, Acetylsalicylic Acid (Aspirin), or other NSAIDs.


Q: Can Bonjela be used by someone who has a history of stomach ulcers?

The salicylate-containing gel is contraindicated for patients who are suffering from active peptic ulceration (a stomach ulcer). Official guidance also advises caution for use in individuals with a history of gastrointestinal disease.


Q: Why is Bonjela advised against if a child has a fever or is recovering from a viral infection?

Official warnings regarding the salicylate-containing product advise against use in children under 16 years of age who have a fever or are recovering from viral infections like chickenpox or influenza. This is because these circumstances have been associated with the theoretical risk of Reye's syndrome when salicylates are used.


Q: Does Bonjela create a protective barrier over a mouth ulcer to aid healing?

The product is classified as a mucoadhesive gel, meaning it is designed to stick to the mouth lining for prolonged contact with the affected area. Its purpose is to relieve pain and help fight minor mouth infection.


Q: What is the difference between Bonjela Adult and Bonjela Cool Mint Gel?

According to official product information, both Bonjela Adult and Bonjela Cool Mint Gel contain the same active ingredient, choline salicylate. The difference between the two products is primarily related to the flavouring excipients used and whether the product is defined as sugar-free.


Q: Are there any known interactions between Bonjela and blood-thinning medications?

Official documents for the salicylate-containing product indicate that salicylates may enhance the effect of anticoagulants (blood-thinning medications). Caution is required if the patient is taking these types of medicines.


Q: What is the reason for the aniseed or licorice flavor in the adult Bonjela formula?

Regulatory labels for the product list specific fragrance excipients, such as anisyl alcohol. These ingredients contribute to the final flavor profile of the gel.


Q: Is there any public information regarding Bonjela potentially affecting a breathalyzer test?

Official documents mention that the medicine contains a small amount of alcohol (ethanol). The amount per dose is noted as being equivalent to less than 2 mL of beer or 1 mL of wine, and it is officially stated that this amount will not have any noticeable effects.


Q: Why was the Bonjela age restriction guidance changed by regulatory agencies?

The restriction on use in children was introduced by regulatory bodies as a precautionary safety measure. This action was taken to align topical salicylate gels with existing advice on oral aspirin, due to the theoretical risk of Reye's syndrome if the product was accidentally overused in children.


Q: Is Bonjela safe for people with diabetes to use?

Official warnings note that individuals with diabetes may need to exercise caution when considering some oral gels. This is because some products containing choline salicylate may contain sugar or similar excipients, and the specific ingredients list should be checked.


Q: Can Bonjela be used for general gum inflammation not caused by a specific ulcer or sore?

Official indications for the product include the symptomatic relief of localized oral soreness, discomfort, and inflammation. This use is generally applied to common mouth ulcers, sores, and irritation related to dentures and orthodontic devices.


Q: What does research evidence suggest about the effectiveness of Bonjela for recurrent mouth ulcers?

Official product indications cover common mouth ulcers, but the research exploring the durability of response or the effects on recurring conditions is noted in regulatory reviews as not being well characterized in the public research record.


Q: What is the official guidance on using Bonjela for children over 16 but under 18?

The salicylate-containing gel is officially labelled for use by Adults and children over the age of 16. The regulatory documents do not indicate that the dosage needs to be modified for individuals in the 16 to 17 age group.


Q: Does the choline salicylate in Bonjela absorb into the bloodstream significantly?

Regulatory warnings indicate that absorption does occur. The risk of systemic toxicity (salicylate poisoning) is officially noted with excessive or frequent application, resulting in high plasma levels.


Q: What are the symptoms of using too much oral gel containing salicylate?

Symptoms of salicylate toxicity, which can result from over-exposure, may include ringing in the ears, dizziness, nausea, and rapid breathing. Regulatory guidance advises that medical attention should be sought if over-exposure is suspected.


Q: Can I use Bonjela with a steroid inhaler or other oral medications?

Official documents note that the salicylate-containing product has a documented interaction with steroid medications, such as prednisone or cortisone. This is due to the potential for additive side effects.


Q: Are there different versions of Bonjela sold in different countries (US vs UK/AU)?

Yes, regulatory and commercial information indicates that different formulations are available globally. For example, some jurisdictions label a salicylate-based product for use in children, while others only approve a lidocaine-based product for infants.


Q: Is Bonjela considered safe for individuals with known liver or kidney conditions?

Official guidance specifies that caution is required for the use of this product in patients with hepatic (liver) or cardiac dysfunction. Warnings related to renal dysfunction (kidney conditions) are also associated with salicylates and should be considered.

How should Bonjela be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and discarding Bonjela (Lidocaine/Cetalkonium Oral Gel) to maintain its integrity and ensure public safety.

Storage Conditions

Requirement Specifics
Temperature Limit Store at a temperature not exceeding 25 C.
Child Safety Must be kept out of the sight and reach of children.
Stability Do not use past the expiry date printed on the carton and tube.

Disposal Rules

Regulatory instructions require proper handling of unused or expired product. The medicine must not be disposed of via wastewater or regular household waste. Instead, individuals should consult a pharmacist and follow local pharmaceutical waste procedures for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bonjela found in:

A-Z Index: